Advanced Prostate Cancer VL

TALAPRO-2 Study Reveals Efficacy and Tolerability of Talazoparib Combination for Prostate Cancer - Neeraj Agarwal

Details
In this conversation, Alicia Morgans and Neeraj Agarwal discuss the TALAPRO-2 trial, a phase three study investigating the effectiveness of combining ADT plus enzalutamide plus talazoparib in treating first line metastatic castrate-resistant prostate cancer. Agarwal presents the study's quality of life data at ASCO 2023, revealing the experimental arm significantly delayed the deterioration of pat...

Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith

Details
Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study's secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival benefit...

Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi

Details
In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study's results, Professor Bossi revealed no overall survival benefit from radiotherapy...

Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study - Fatima Karzai & Rana McKay

Details
Alicia Morgans host Fatima Karzai and Rana McKay to explore the National Cancer Institute Natural History Study. This study focuses on prostate cancer patients with unusual mutations and exceptional responses to treatments, aiming to understand their disease progression over time. The trial, conducted across multiple sites including UCSD, follows participants longitudinally, particularly those wit...

Unlocking Prostate Cancer Therapeutics: The Potential of Minor Spliceosome Inhibition - Mark Rubin

Details
In this conversation, Andrea Miyahira is joined by a research team including Anke Augspach, Rahul Kanadia, and Mark Rubin. They discuss their paper, "Minor Intron Splicing is Critical for Survival of Lethal Prostate Cancer". The paper dissects the role of minor introns, which constitute less than 0.5% of all introns, in gene expression and their involvement in prostate cancer onset and progression...

Investigating the Role and Therapeutic Potential of B7-H3 in Prostate Cancer - Christina Guo

Details
Christina Guo elaborates on her and her colleagues' findings published in European Urology, titled "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer". Dr. Guo's research focuses on B7-H3, an immunomodulatory glycoprotein overexpressed in prostate cancers. The team investigated B7-H3 expression in treatment-naive and castration-resistant prostate cancer biopsies, analyzing the protein's co...

Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies - Di Zhao

Details
Andrea Miyahira invites Di Zhao to discuss her research published in Science Translational Medicine entitled “Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.” Dr. Zhao's team explored immune checkpoint B7-H3, identified as a promising target for advanced prostate cancer with PTEN and p53 deficiencies. Their analysis of immune checkpoi...

Combination Treatment in Metastatic Prostate Cancer: Is the Bar Too High or Have We Fallen Short? - Kenneth Chen

Details
Alicia Morgans hosts Kenneth Chen to discuss a Nature Reviews publication on combination treatment in metastatic prostate cancer. Chen explains the paper's inspiration was drawn from observing subgroups of patients failing to receive the established standard of care. Chen identifies factors that influence patients' access to effective treatments, including cost, reimbursement models, availability...

PSMA Expression in Advanced Prostate Cancer: Implications for Targeted Therapies

Details
In a discussion with Andrea Miyahira, Himisha Beltran discusses her team's research on Prostate-Specific Membrane Antigen (PSMA) heterogeneity and regulation in metastatic prostate cancer. The study, led by Martin Bakht, explores the varied levels of PSMA expression in metastases of androgen receptor-positive prostate cancer, as well as the regulation of PSMA in AR-negative and neuroendocrine pros...

Insights into Global Treatment Patterns for Advanced Prostate Cancer: The IRONMAN Registry - Lorelei Mucci &. Dan George

Details
Lorelei Mucci and Daniel George join Alicia Morgans to discuss the IRONMAN registry, the International Registry for Men with Advanced Prostate Cancer. The registry has actively enrolled 3,200 patients with hormone-sensitive or castration-resistant prostate cancer from 14 countries worldwide. The registry includes a diverse population in terms of geography, socioeconomic status, the type of center...